SNMMI is a global and collaborative scientific organization dedicated to both the practice and the science of nuclear medicine and molecular imaging and therapy around the world. SNMMI's worldwide membership totals more than 18,000, including physicians, scientists, technologists, chemists, radiopharmacists, students and industry representatives from 76 countries around the world.
SNMMI is a global and collaborative scientific organization dedicated to both the practice and the science of nuclear medicine and molecular imaging and therapy around the world. SNMMI's worldwide membership totals over 18,000, which includes physicians, scientists, technologists, chemists, radiopharmacists, students and industry representatives from more than 75 countries around the world. SNMMI's Journal of Nuclear Medicine (JNM), the premier international journal of nuclear medicine, reaches over 18,000 individuals each month. SNMMI's Annual Meeting is nuclear medicine's and molecular iamging's largest gathering each year, attracting over 4,000 professional attendees and another 2,500 industry representatives.
At the most recent Annual Meeting in June 2013 in Vancouver, BC, Canada, 38% of registered attendees were from countries other than the United States. Attendees represented over 69 countries. In addition, abstract submissions for SNMMI's Annual Meeting from outside the United States represent close to 65% of all submissions.
While SNMMI's headquarters office resides in Virginia, just outside of Washington, D.C., its perspective, programs, and growth are as international as its members. As of 2013, more than 11.8% of the Society's members reside in more than 75 countries other than the United States.
Search for an international nuclear medicine and molecular imaging organization near you.
SNMMI's educational programs and activities reflect the increasing importance and participation of its international members. Such common global nuclear medicine and molecular imaging and therapy issues as quality of care, educating referring physicians and patients, and exploring ways to better share developments in the practice of nuclear medicine and molecular imaging and therapy are but a few of the activities currently underway by Society staff, Committees, Councils, and our Centers of Excellence. This website seeks to constantly expand its offerings to the Society's international members, providing an ever-changing, updated array of global resources and news for nuclear medicine and molecular imaging and therapy professionals literally anywhere on the globe.
SNMMI continues to stay actively involved in several jointly sponsored educational programs and educational outreach activities with regional nuclear medicine and molecular imaging and therapy organizations around the world; both in their home countries, and during SNMMI's Annual Meeting. These joint sponsored programs include not only the sharing of speakers and renown experts on all facets of nuclear medicine and molecular imaging, collaboration on the development of enduring educational materials, and programmatic/administrative support, but also include translation of materials and website development.
Each year, the SNMMI collaborates with international organizations in an effort to continue the exchange of ideas, education and knowledge. Intiatives include:
Nuclear Medicine Global Initiative
3rd Sino-American Conference
Chinese/U.S. Resident Exchange Program
IAEA CT Case Webinar Series
EANM Collaborative Guidelines
Attention young professionals including those in training (residents, physicians, nuclear pharmacists, or scientists) or in practice within 10 years of graduation:
The American College of Nuclear Medicine (ACNM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) will soon be accepting the abstracts for the ACNM Annual Meeting and SNMMI 2016 Mid-Winter Meeting January 28-31, 2016 in Orlando, FL.
Clinical and scientific abstracts will be accepted on the following topics:
Abstract Submissions Open Wednesday, August 26, 2015.
SNMMI offers a Full International Membership category for inernational colleagues. Learn more on how to become an SNMMI Full Member (international).
Available to physicians, scientists or pharmacists possessing an advanced degree who have presented credentials indicating their professional activity, either, medical, paramedical, investigational or educational in the scientific or clinical disciplines of molecular imaging or nuclear medicine. This includes the diagnostic, therapeutic or investigational use of radionuclides or other molecular imaging technologies.
Annual dues: $460
Includes subscription to The Journal of Nuclear Medicine.
Includes voting rights and can be elected an Officer of the SNMMI.
As part of its continuing commitment to growing the practice of nuclear medicine and molecular imaging and therapy worldwide, SNMMI leadership works diligently to develop strategic alliances with key regional nuclear medicine organizations to assist these groups in expanding the scope and quality of nuclear medicine outside the United States. These strategic alliances stretch across the globe. reaching every continent where SNMMI's members reside and practice.
SNMMI Partners and Alliances Include:
For more information on SNMMI's international activities and programs, please contact:
Nikki Wenzel-Lamb, MBA Director of Leadership Direct: 703-652-6766 Fax: 703-708-9020 Email: firstname.lastname@example.org
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is pleased to announce the recipients of the 2015-2017 SNMMI Wagner-Torizuka Fellowship.
The American College of Nuclear Medicine (ACNM) and SNMMI are now accepting abstracts for the ACNM Annual Meeting and SNMMI 2016 Mid-Winter Meeting—January 28-31, 2016 in Orlando, FL.
On Wednesday, August 26, SNMMI submitted comments to CMS on the CY 2016 Proposed Rules for the Hospital Outpatient Prospective Payment System (HOPPS) and the Medicare Physician Fee Schedule (MPFS).
(Government Relations News)
Researchers have discovered that PET imaging with a specific biomarker can detect a fast-growing primary prostate cancer and is better able to differentiate it from benign prostate lesions, a process that they hope could eventually replace the traditional ultrasound-guided 12-core biopsy.
(MI: Making a Difference)
CTN Oncology Phantom Scanner Validation Results: What Does the Data Mean?
October 15, 2015 at 3:00 pm ET
Speaker: John Sunderland
This webinar will examine the data collected from the SNMMI Clinical Trials Network Oncology Phantom. Since its inception in 2008, the Clinical Trials Network has collected over 400 sets of phantom data from over 230 scanners located at imaging sites world-wide using the CTN oncology clinical simulator phantom. These scanners include most commercially-available PET/CT systems, ranging from the older, basic models to the most current state-of-the-art systems. The overall set-up and management of this unique program along with results from the acquired data offer participants vital information on the importance of standardizing reconstruction parameters and performing rigid, ongoing quality control of your PET/CT system.
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.
Learn more about journals published by or sponsored by the Society of Nuclear Medicine and Molecular Imaging.